Bonetrap®5b　（抗酒石酸酸性磷酸酶5b）
——骨吸收指标

TRACP 5和TRACP 5b的差异
TRACP 5来源于巨噬细胞和破骨细胞，但和骨TRACP具有高特异性的酶，只来源于破骨细胞。大约有90%参与循环的是TRACP的同型异构体5a，因此在检测骨吸收时，检测高特异性的TRACP5b有很重要的意义。

关于骨TRACP5b的检测
1、 源于特异性破骨细胞和破骨细胞的数量呈相关性
2、 低的昼夜变化，肝病、肾病对它无影响
3、 同样可以用大鼠和小鼠来实验
4、 TRACP5b是专利技术
5、 TRACP5b的用来调查研究如下：
 －可用于早期骨质检测，预防骨质疏松的恶化及测定骨吸收亢进的病人，如原发性骨质疏松和肾性骨病；
 －可预测骨折的危险性，并用于评估骨吸收治疗的疗效；
 －可对血液透析及肾移植疗效进行监测；
 －鉴别诊断与疼痛症状有关的颈椎病、肩周炎、腰椎病、痛风、关节炎等；
 －在肿瘤病人中当TRACP5b的活力增高提示肿瘤骨转移或存在多发性骨髓瘤。


TRACP5b是骨生化标志物唯一应用在：
骨疾病 　骨吸收
骨质疏松症
变形性骨炎
癌症 癌症骨转移
多样性骨髓瘤
慢性肾病 血液透析
肾移植


其它资料
BoneTRAP 酶联免疫实验，用抗酒石酸酸性磷酸酶5b，检测人破骨细胞培养介质。
RatTrap 酶联免疫实验，用抗酒石酸酸性磷酸酶5b，检测大鼠破骨细胞培养介质。
MouseTrap 酶联免疫实验，用抗酒石酸酸性磷酸酶5b，检测小鼠破骨细胞培养介质。



http://www.gucon.com/P_Info.asp?Id=4

科技奖项:

1st Prize in the National Competition for New Finnish Inventions by the Foundation of New Technology, 2001. BoneTRAP assay by Jussi Halleen and Kalervo Väänänen.

2nd Prize in the President of Finland’s Innosuomi 2000 Competition for New Finnish Inventions. BoneTRAP assay by Jussi Halleen and Kalervo Väänänen.

1st Prize in the Best Finnish Bone Research 2000-competition by Finnish Bone Society: “Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK 2000 Tartrate-Resistant Acid Phosphatase 5b, a Novel Serum Marker of Bone Resorption. J Bone Miner Res 15:1337-1345.”

相关文献：
１. Rissanen JP, Suominen MI, Peng Z, Halleen JM 2008 Secreted Tartrate-Resistant Acid Phosphatase 5b is a Marker of Osteoclast Number in Human Osteoclast Cultures and the Rat Ovariectomy Model. Calcif Tissue Int 82:108-115.
２. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK 2006 Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 52:499-509.
３. Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Väänänen HK, Suominen P, Helenius H, Salminen E 2006 Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 26:3127-3132.
４. Fagerlund KM, Ylipahkala H, Tiitinen SL, Janckila AJ, Hamilton S, Mäentausta O, Väänänen HK, Halleen JM 2006 Effects of proteolysis and reduction on phosphatase and ROS-generating activity of human tartrate-resistant acid phosphatase. Arch Biochem Biophys 449:1-7.
５. Wang Q, Alen M, Nicholson PH, Halleen JM, Alatalo SL, Ohlsson C, Suominen H, Cheng S 2006 Differential effects of sex hormones on peri- and endocortical bone surfaces in pubertal girls. J Clin Endocrinol Metab 91:277-282.
６. Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, Väänänen HK 2005 Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol 44:742-747.
７. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen HK, Halleen JM 2005 Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover. J Bone Miner Res 20:1804-1812.
８. Perez-Amodio S, Vogels IM, Schoenmaker T, Jansen DC, Alatalo SL, Halleen JM, Beertsen W, Everts V 2005 Endogenous expression and endocytosis of tartrate-resistant acid phosphatase (TRACP) by osteoblast-like cells. Bone 36:1065-1077.
（略）